- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00484185
Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B
Post Marketing Surveillance To Observe Safety And Efficacy Of BeneFIX In Patients With Hemophilia B
To provide safety and effectiveness information of BeneFIX during the post-marketing period as required by Korea FDA regulations, to identify any potential drug related treatment factors in Korean population including:
1) Unknown adverse reactions, especially serious adverse reactions; 2) Changes in the incidences of adverse reactions under the routine drug uses.
3) Factors that may affect the safety of the drug 4) Factors that may affect the effectiveness of the drug
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 137-882
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients or legally authorized representatives of pediatric patients agree to provide written informed consent form (data privacy statement).
- Pediatric and adult patients who have been treated with original or reformulated BeneFIX for hemophilia B (congenital factor IX deficiency or Christmas disease) from first approved date by KFDA, or who are planned to be newly prescribed BeneFIX (for example, patients switching from pdFIX to BeneFIX).
Exclusion Criteria:
- Patients with a known history of hypersensitivity to original or reformulated BeneFIX or any component of the product.
- Patients with a known history of hypersensitivity to hamster protein.
- Patients participating in an interventional trial of any investigational drug or device.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
|
BeneFIX will be administered according to physician's discretion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events (AEs) According to Baseline Characteristics
Time Frame: Baseline up to 6 months
|
AE: any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.
AE assessed by baseline characteristics (chr) included age, gender, pediatric/geriatric status, liver disorder, BeneFIX treatment (previously/newly), factor nine (FIX) gene mutation, prior exposure to plasma-derived FIX products, prior FIX regimen(s) utilized, personal history of FIX inhibitor, family history of hemophilia B, severity of bleeding, medical history, concomitant medication and therapy.
|
Baseline up to 6 months
|
Number of Participants With Adverse Events (AEs) According to Severity
Time Frame: Baseline up to 6 months
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
AE was assessed according to severity; mild (not causing any significant problem, dose adjustment not required), moderate (caused problem that does not interfere significantly with usual activities or the clinical status, dose adjustment needed due to adverse event) and severe (caused problem that interferes significantly with usual activities or the clinical status, study drug stopped due to adverse event).
|
Baseline up to 6 months
|
Number of Participants With Action Taken in Response to Adverse Events (AEs)
Time Frame: Baseline up to 6 months
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
After an onset of an AE, relevant actions were undertaken on the study drug or the participant.
Actions related to study drug included: dosage reduced, dosage increased, stopped temporarily or permanently, no action taken; actions related to participants included: withdrawal from the study, concomitant medication, no action taken or any other as per physician's discretion.
|
Baseline up to 6 months
|
Number of Participants With Adverse Events (AEs) According to Seriousness
Time Frame: Baseline up to 6 months
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Seriousness of an AE was assessed under the criteria of serious adverse event (SAE).
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Baseline up to 6 months
|
Number of Participants With Outcome in Response to Adverse Events (AEs)
Time Frame: Baseline up to 6 months
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Outcome of an AE was assessed based on response to a question 'Is the adverse event still present?' as 'yes', 'unknown' or 'no-resolved'.
|
Baseline up to 6 months
|
Number of Participants With Adverse Events (AEs) by Relationship
Time Frame: Baseline up to 6 months
|
AE: untoward medical occurrence in participant who received study drug without regard to causal relationship.
All causalities and drug-related AEs reported.
Drug-related AEs based on physician's discretion: certain (AE after drug intake, not explained by other drugs, reaction on drug cessation [DC], relapse on re-intake of drug), probable/likely (AE after drug intake, not explained by other drugs, reaction on DC, no information on re-intake), possible (AE after drug intake, explained by other drugs, no information on DC), unlikely (not related to drug intake time, explained by other drugs).
|
Baseline up to 6 months
|
Number of Participants With Unexpected Adverse Events (AEs)
Time Frame: Baseline up to 6 months
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Unexpected AEs were those that were not included in precaution of local product document.
|
Baseline up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Annualized Bleeding Rate (ABR)
Time Frame: Baseline up to 6 months
|
An annualized bleeding rate (ABR) was calculated as the number of bleeds requiring administration of BeneFIX (for on-demand therapy and surgery), divided by total period of bleeding multiplied by 365.25.
Total period of bleeding is the number of days on treatment for prophylaxis purpose and on-demand therapy and surgery.
|
Baseline up to 6 months
|
Number of Responses to On-demand Treatment With Study Medication
Time Frame: Baseline up to 6 months
|
Responses to on-demand treatment were rated by participant/caregiver or physician each time the drug was administered, on 4-point scale.
Score 1=excellent (definite pain relief [PR] and improvement [imp] within 8 hours [h] of infusion [inf], no additional inf); score 2=good (definite PR and imp within 8h of inf, at least 1 additional inf for complete resolution [CR] of bleeding or starting after 8h of inf, no additional inf); score 3=moderate (probable or slight imp starting after 8h of inf, at least 1 additional inf for CR of bleeding); score 4=no imp at all, or condition worsens).
|
Baseline up to 6 months
|
Mean Number of Infusion of Study Medication
Time Frame: Baseline up to 6 months
|
Mean frequency of BeneFIX administration of each participant was calculated from number of BeneFIX infusions which each participant received for treatment of each new bleed.
Mean frequency of BeneFIX administration for total participants was summarized.
|
Baseline up to 6 months
|
Mean Number of Breakthrough Bleeds Within 48 Hours of Study Medication
Time Frame: Baseline up to 6 months
|
Mean frequency of breakthrough (spontaneous/non-traumatic) bleeds of each participant within 48 hours of a preventive/prophylaxis dose of BeneFIX was calculated from number of irregular bleeding which occurred in each participant.
Mean frequency breakthrough bleeds for total participants within 48 hours of a preventive/prophylaxis dose of BeneFIX was summarized.
|
Baseline up to 6 months
|
Average Infusion Dose of Study Medication
Time Frame: Baseline up to 6 months
|
Average of dose per infusion per kilogram (kg) body weight was reported for prophylaxis purpose or on-demand therapy and surgery.
|
Baseline up to 6 months
|
Total Infusion of Study Medication
Time Frame: Baseline up to 6 months
|
Total dose of study drug infused was calculated over the study duration.
|
Baseline up to 6 months
|
Percentage of Participants With Efficacy Evaluation
Time Frame: Baseline up to 6 months
|
The efficacy of study drug was rated as 'very effective', 'effective', 'slightly ineffective' and 'ineffective'.
|
Baseline up to 6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Adverse Events (AEs)
Time Frame: Baseline up to 6 months
|
Total time from onset of adverse event till the event is resolved.
Duration of AE per event = AE stop date minus AE start date plus 1.
|
Baseline up to 6 months
|
Number of Participants Who Discontinued the Study Due to Adverse Events (AEs)
Time Frame: Baseline up to 6 months
|
AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Number of participants who discontinued the study due to AEs was reported.
|
Baseline up to 6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3090X1-4403
- B1821005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemophilia B
-
Catalyst BiosciencesCompletedHemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without InhibitorBulgaria, Russian Federation
-
BayerCompletedHemophilia A; Hemophilia BIsrael
-
American Thrombosis and Hemostasis NetworkTakeda; CSL Behring; OctapharmaCompletedHemophilia A | Hemophilia B | Hemophilia | Hemophilia A With Inhibitor | Haemophilia | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
American Thrombosis and Hemostasis NetworkGenentech, Inc.Active, not recruitingHemophilia A With Inhibitor | Hemophilia B With Inhibitor | Haemophilia A Without Inhibitor | Haemophilia B Without InhibitorUnited States
-
Laboratoire français de Fractionnement et de BiotechnologiesLFB USA, Inc.CompletedA Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (PERSEPT2)Hemophilia A With Inhibitors | Hemophilia B With InhibitorsBulgaria, Ukraine, Czechia, United States, Georgia, South Africa
-
University College, LondonRecruiting
-
University of British ColumbiaBiogenCompletedHemophilia A, Congenital | Hemophilia B, CongenitalCanada
-
Catalyst BiosciencesCompletedHemophilia A With Inhibitor | Hemophilia B With InhibitorArmenia, Georgia, South Africa, Poland, Russian Federation
-
CSL BehringTerminatedHemophilia A With Inhibitors | Hemophilia B With InhibitorsGeorgia, Italy, Malaysia, Russian Federation, South Africa, Spain, Thailand, Ukraine, United Kingdom
-
Affiliated Hospital of Guangdong Medical UniversityNot yet recruitingHemophilia B Without Inhibitor
Clinical Trials on BeneFIX (coagulation factor IX (recombinant))
-
PfizerCompletedHemophilia BUnited States, Spain, Croatia, Serbia, Russian Federation, Canada, Hungary, Italy, Romania
-
Grifols Biologicals, LLCCompleted
-
Bioverativ Therapeutics Inc.Swedish Orphan BiovitrumCompletedSevere Hemophilia BSweden, United States, France, Italy, Russian Federation, United Kingdom, Germany, China, Poland, Japan, Australia, Brazil, Canada, India, South Africa, Hong Kong, Belgium
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Baxalta now part of ShireTakedaCompleted
-
Baxalta now part of ShireCompletedHemophilia BPoland, United Kingdom, Spain, Bulgaria, Romania, Japan, Russian Federation, Brazil, Chile, Sweden, Colombia, Ukraine, Argentina, Czechia
-
Medexus Pharma, Inc.CompletedHemophilia BUnited States, France, United Kingdom, India, Israel, Italy, Poland
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireCompleted
-
Bioverativ Therapeutics Inc.Swedish Orphan BiovitrumCompletedHemophilia BUnited States, United Kingdom, South Africa, Netherlands, Ireland, Australia
-
CSL BehringCompletedHemophilia BBulgaria, Israel